[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564428":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":58,"collaborators":61,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":10,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":10,"maxAge":10,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Shanghai Jiao Tong University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"berberine",null,"post-intervention of berberine",[13],"Drug: Berberine Hydrochloride",{"label":15,"type":10,"description":16,"interventionNames":17},"placebo","post-intervention of placebo tablets",[18],"Drug: Placebo",[20,24],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":10},"DRUG","Berberine Hydrochloride",[9],{"type":21,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Placebo","Looks the same as berberine",[15],[29],{"name":30,"affiliation":31,"role":32},"Jing-Yuan Fang, M.D, Ph.D","RenJi Hospital","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Jing-Yuan Fang, Professor","CONTACT","021-13918386561","jingyuanfang@sjtu.edu.cn",[40],{"facility":41,"status":42,"city":43,"state":10,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Renji Hospital, Shanghai Jiao-Tong University School of Medicine","RECRUITING","Shanghai","200127","China","CN",{"type":48,"coordinates":49},"Point",[50,51],121.45806,31.22222,{"lat":51,"lon":50},[54],{"name":55,"role":36,"phone":56,"phoneExt":10,"email":57},"Yun-Yue Guo","021-68383312","guoyunyue@renji.com",{"type":32,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jing-yuan Fang, MD, Ph. D","Division of Gastroenterology & Hepatology, Renji Hospital",[62,64,66,68,70,72],{"name":63,"class":6},"Seventh Medical Center of PLA Army General Hospital",{"name":65,"class":6},"Zhongshan Hospital Xiamen University",{"name":67,"class":6},"Nanfang Hospital, Southern Medical University",{"name":69,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"name":71,"class":6},"Tianjin Medical University General Hospital",{"name":73,"class":74},"the Tenth People's Hospital affiliated to Tongji University","UNKNOWN","100564428","6-year-follow-up-data-after-the-berberine-intervention-trial-100564428",false,"NCT06629051","6-year Follow-up Data After the Berberine Intervention Trial","A Multicenter, Placebo-controlled Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas：6-year Retrospective Follow-up Data","Inclusion Criteria: participants who completed the previous berberine intervention study (NCT02226185) Exclusion Criteria: no","ALL",{"count":84,"type":85},891,"ESTIMATED","OBSERVATIONAL","Colorectal cancer (CRC) is a common malignancy of the digestive tract, which constitutes a major public health burden. Almost 90% of CRC cases progress from precursor adenomatous polyps through adenoma-carcinoma sequence. Endoscopic detection and removal of colorectal adenoma (CRA) could reduce the incidence and mortality risk of CRC, but the recurrence rate is still high. Therefore, chemoprevention is quite important, not only solve the urgent public health problem, but also be cost-effective.\n\nIn 2020, the investigators published a multicenter, randomized, double-blind, placebo-controlled clinical study (NCT02226185) in the Lancet Gastroenterology \\& Hepatology. The result concluded that oral BBR for 2 years significantly reduced recurrence after endoscopic removal of CRA (RR 0.77, 95%CI 0.66-0.91; p=0.001). BBR also has a significant preventive effect on all polypoid lesions, including adenomas and serrated lesions (adjusted RR 0.78, 95%CI 0.66-0.91; p=0.002) . Does BBR still have a long-term protective effect on the recurrence of CRA after discontinuation? That's what the investigators concerned.\n\nThe present study is performed to observe and compare retrospectively the recurrence rate of CRAs in patients of the original BBR RCT study (NCT02226185) within 6 years after discontinuation of medication, including the overall recurrence rate of traditional adenomas within the first year, 1-3 years, 3-6 years, and the entire follow-up period of 6 years. The aim is to evaluate the long-term efficacy of BBR in preventing recurrence and carcinogenesis after endoscopic resection of CRAs.",[89,90,91],"Colorectal Adenoma","Colorectal Cancer Control and Prevention","Colorectal Polyps",[9,93,94,95,96],"colorectal adenoma","colorectal cancer","long term chemoprevention","colorectal polyps","2024-10-04",{"date":99,"type":100},"2024-10-08","ACTUAL",{"date":97,"type":85},{"date":103,"type":85},"2024-12-31",{"name":5,"class":6},1]